New stock news | Micotan once again submits application to Hong Kong Stock Exchange

According to the disclosure on March 11 by the Hong Kong Stock Exchange, Shenzhen Maiketen Biomedical Technology Co., Ltd. (referred to as Maiketen) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Morgan Stanley and Huatai International as joint sponsors. The company had submitted its prospectus to the Hong Kong Stock Exchange on September 11, 2025. The prospectus shows that Maiketen is a global medical device provider that meets the clinical needs of a wide range of clinical departments, wards, clinics in medical institutions, community health centers, laboratories, and home care settings. As of December 31, 2025, the company's product portfolio includes over 60 life support products, 110 minimally invasive interventional products, and 160 in vitro diagnostic products.